BMS sues MSN over Pomalyst generic

Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst (Pomalidomide), which it claims infringes six patents owned by BMS’ subsidiary Celgene.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

BMS says Hengrui’s Abraxane infringes

13 May 2022 A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

6 September 2021 In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.

More on this story

Generics

BMS says Hengrui’s Abraxane infringes

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

More on this story

Generics

BMS says Hengrui’s Abraxane infringes

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis